Solid Biosciences
Open
$7.26
Prev. Close
$7.27
High
$7.27
Low
$7.25
Market Snapshot
$549.27M
-3.2
-3.06
100
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
emptyResult
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Recently from Cashu
Solid Biosciences' SGT-003: Hope for DMD Amid Urgent Need Following Patient Losses
Innovative Gene Therapy Takes Center Stage Amid DMD Patient Losses Recent fatalities involving two patients with Duchenne muscular dystrophy (DMD) have cast a spotlight on the urgent need for effectiv…
Solid Biosciences' SGT-003: Pioneering Gene Therapy for DMD Amid Recent Tragedies
Gene Therapy Innovation in the Wake of Tragedy: Solid Biosciences' SGT-003 at the Forefront Recent fatalities involving two patients with Duchenne muscular dystrophy (DMD) underscore the urgent need f…
Solid Biosciences Advances SGT-001 Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences Advances Gene Therapy for Duchenne Muscular Dystrophy Solid Biosciences, a biotechnology firm focused on developing gene therapies for Duchenne muscular dystrophy (DMD), announces a…
Solid Biosciences Makes Strides in Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences Advances Gene Therapy Solutions for Duchenne Muscular Dystrophy Solid Biosciences, a biotechnology company focused on advancing innovative treatments for Duchenne Muscular Dystrophy…